Prescriber's Letter | Unbiased Medication Updates & CME

March 2025 Issue

Break Down Barriers to Dispensing Buprenorphine for OUD

You play a crucial role in ensuring patients have access to buprenorphine products (Suboxone, etc) for opioid use disorder (OUD)...

Resources

FAQ: Management of Opioid Use Disorder

Cut to the Chase About Whether It’s Okay to Cut Patches

Dangerous errors with transdermal patches are still occurring...

Explain How Suzetrigine Stacks Up for Acute Pain

The spotlight is on suzetrigine (Journavx), the first med in a new class of NON-opioid analgesics for acute pain in over 2 decades...

Stay Current on Med Recommendations for Diabetes

You’ll continue to see SGLT2 inhibitors and GLP-1 agonists gain traction as first-line agents for many adults with type 2 diabetes...

GO TO FULL ISSUE

CE & Training

NEW REQUIRED COURSE: Substance Use Disorders and Pain Management: MATE Act Training

CE-IN-THE-LETTER: Prescriber Insights March 2025

LIVE CE: Meds for Opioid Use Disorder: Buprenorphine and Beyond

PODCAST CE: Medication Talk - Bronchitis and Pneumonia Treatment

GO TO CE & TRAINING ORGANIZER

Featured Clinical Resources

GO TO ALL CLINICAL RESOURCES >

What is Prescriber Insights?

Prescriber Insights is the fastest, most trustworthy way for physicians, APRNs, and PAs to find out how drug therapy changes should fit into your practice. It's unbiased, evidence-based, and 100% free from financial support of the pharma industry. Learn more >

Group Purchases & Pricing

Prescriber Insights is eligible for bulk discounts. Customize CE and compliance training assignments. Easily manage users and run reports. Bundle with other products for significant savings. Request information

Group Purchases & Pricing

Prescriber's Letter is eligible for bulk discounts. Customize CE and compliance training assignments. Easily manage users and run reports. Bundle with other products for significant savings. Request information